Navigation Links
Cantel Medical Corp. to Hold Conference Call to Discuss Results for Its First Quarter Ended October 31, 2008
Date:12/2/2008

LITTLE FALLS, N.J., Dec. 2 /PRNewswire-FirstCall/ -- Cantel Medical Corp. (NYSE: CMN) will hold a conference call to discuss the Company's results for its first quarter ended October 31, 2008 on December 5, 2008 at 11:00 AM ET. Participating in the call will be Charles M. Diker, Chairman; Andrew A. Krakauer, President; Craig A. Sheldon, Senior Vice President and CFO; and Roy K. Malkin, President of Minntech Corporation. Minntech is a Cantel subsidiary. The first quarter results will be announced on December 5 before the market opens.

To participate in the conference call, dial 877-407-8035 approximately 5 to 10 minutes before the beginning of the call. If you are unable to participate, a digital replay of the call will be available from Friday, December 5, 2008 at 2:00 PM through midnight on December 6, 2008 by dialing (877) 660-6853 and using pass code # 286 and conference ID # 305374.

The call will be simultaneously broadcast live over the Internet on vcall.com at http://www.investorcalendar.com/IC/CEPage.asp?ID=138525. A replay of the web cast will be available on Vcall for 30 days.

About Cantel Medical Corp.

Cantel Medical Corp. (NYSE: CMN) is a leading provider of infection prevention and control products in the healthcare market. Cantel's products include specialized medical device reprocessing systems for renal dialysis and endoscopy, dialysate concentrates and other dialysis supplies, disposable infection control products primarily for the dental industry, water purification equipment, sterilants, disinfectants and cleaners, hollow fiber membrane filtration and separation products for medical and non-m
'/>"/>

SOURCE Cantel Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Cantel Medical Corp. to Present at the Oppenheimer & Co. 19th Annual Healthcare Conference
2. Cantel Medical to Relocate Dutch Manufacturing Operations to the United States to Achieve Operating Savings
3. Cantel Medical Corp. and National Safety Council Launch Joint Initiative to Prepare Businesses and Individuals for Flu Pandemic
4. New Report Recommends Strategies to Reduce Medical Resident Fatigue-Related Errors and Improve Training
5. Revised hours and workloads for medical residents needed to prevent
6. Consumers Uncertain About Their Medical Diagnosis & Treatment
7. Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial
8. Levaquin is the Preferred Quinolone Among More Than Half of All General Medical-Surgical Hospitals in the United States
9. China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO
10. The National Health Service and Attainia Move to Modernize Medical Capital Equipment Budgeting and Planning for the United Kingdom
11. Encouraging Prospects for Medical Imaging Equipment Services in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2009)...NFORD, Calif. The newest revolution in microbiolog...t,s the hair sheep, a less-hirsute version of the ...m the Stanford University School of Medicine, whic...hat not only are these ruminants low-maintenance a...donors for the microbiology tests necessary to dia...
(Date:7/3/2009)...ROIT, July 3 Ramsy Darwish knows w...medication. In a recent story called America,s "... with CNN,s Rick Sanchez, Ramsy shared his story ...ally ending up at the Narconon Freedom Center ...(Photo 72dpi: Send2Press.com/mediaboom/09-0703-N...
(Date:7/3/2009)...ons drugs may thwart treatment-resistant strain, s...hDay News) -- Extreme drug-resistant tuberculosis ... to treat Parkinson,s disease, suggests a new stud...ersity of California, San Diego, report in the Jul...mercially available entacapone and tolcapone have ...
(Date:7/3/2009)...hers express hope that finding will lead to treatm...s) -- U.S. researchers say they,ve found a major ...elapsed lung cancer. , When caught early, lung ...t detected until the disease is well advanced. Tho...ssion, the disease often springs back more virulen...
Breaking Medicine News(10 mins):Health News:Rare sheep could be key to better diagnostic tests in developing world, says Stanford study 2Health News:Rare sheep could be key to better diagnostic tests in developing world, says Stanford study 3Health News:Narconon Graduate Successfully Recovers From Prescription Drug Abuse 2Health News:New Weapons in Fight Against TB? 2Health News:Cell Pathway May Be Key to Lung Cancer's Spread 2Health News:Cell Pathway May Be Key to Lung Cancer's Spread 3
...300 is used for heart diseases, and prevents the r...re likely to result // in allergic reactions, the...ng to recent studies. The Northwestern Memorial H...d that the use of drug-eluting stent should not be...
...as been devised that can predict the potential att... is that it would help to asthmatics control their... of new drugs. The prediction over the likelihood...over the next month was made by looking at peak fl...
... can now be used to predict the possibility of an ...tool. //It is believed that this finding would hel...ead to the development of better treatment strateg...em called the chaos model (currently applied to co...
... that every patient referral from a GP in England ...system by the end // of this month. But ministers ...for which figures are available - barely 2.7 per c...his way. The Department of Health figures show tha...
Other Medicine News:Health News:Mathematical Model Can Now Help Predict Asthma Risk 2Health News:GP's online referral scheme in UK 'a national IT disaster' 2
(Date:6/29/2009)...Study Seeks to Assess RSV Burden in Outpatient Set...ment to Pediatric Research , , GAITHERSBURG, ...o advance its commitment to pediatric research wit...prospective study designed to assess the burden of...nfants 32-to-35 weeks gestational age (GA) in outp...
(Date:6/29/2009)...or abdominal surgery patients achieved primary and...June 29 AcelRx Pharmaceuticals, In...d Phase 2 clinical study evaluating the safety and...r the management of acute post-operative pain in p...ization. Compared to placebo, patients receiving A...
(Date:6/29/2009)...TON, England, June 29 Vantia Thera...oping novel, small molecule drugs,targeting large...results from,a Phase IIa clinical trial of its le...e trial showed that oral VA106483 was successful i...etic effect in patients, as determined by,increas...
(Date:6/28/2009)...E DO CORONADO, Portugal, June 29 D...at add-on treatment with the novel,once-daily an... ESL) resulted,in a marked and sustained decrease... Results from the one-year extension of a pivot...resented at the International Congress for Epileps...
Breaking Medicine Technology:MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants 2AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 2AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 3AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 4Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 2Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 3Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 2Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 3Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 4Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 5Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 6Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 7Mindray to Unveil Three New Products and Reagents at AACC Annual Meeting 24144 1Mindray to Unveil Three New Products and Reagents at AACC Annual Meeting 24144 2Mindray to Unveil Three New Products and Reagents at AACC Annual Meeting 24144 3HistoRx Names Bill Sullivan Senior Vice President Diagnostic Operations 6613 1HistoRx Names Bill Sullivan Senior Vice President Diagnostic Operations 6613 2HistoRx Names Bill Sullivan Senior Vice President Diagnostic Operations 6613 3BioMS Medicals relapsing remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board 6610 1BioMS Medicals relapsing remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board 6610 2Cynosure Introduces Affirm CO2 28TM 29 Workstation for Advanced Ablative Therapy 6607 1Cynosure Introduces Affirm CO2 28TM 29 Workstation for Advanced Ablative Therapy 6607 2Cynosure Introduces Affirm CO2 28TM 29 Workstation for Advanced Ablative Therapy 6607 3Cynosure Introduces Affirm CO2 28TM 29 Workstation for Advanced Ablative Therapy 6607 4
...IRE)--Mar 6, 2007 - POZEN Inc.,(NASDAQ: POZN), tod...n" PA 325 proof-of-concept study conducted during ...ormulation of 325mg of,aspirin surrounded by a 20m... proton pump inhibitor., The PA 325, 28 day study,...f 50. Each subject was treated with either once a ...
...LL, N.C., US, March 06, 2007,/PRNewswire/ -- AOP O...io, Inc. ("Lantibio") today announced positive fin...linded Phase II clinical,study of Moli1901, an exp.... Moli1901 is being developed by AOP Orphan in,Eur...ent with,Lantibio. The study, performed at multipl...
Other Medicine Technology:POZEN Announces Positive Outcome for PA 325 Proof of Concept Study 2POZEN Announces Positive Outcome for PA 325 Proof of Concept Study 3AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II,Study with Novel Cystic Fibrosis Therapy 2AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II,Study with Novel Cystic Fibrosis Therapy 3AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II,Study with Novel Cystic Fibrosis Therapy 4
...n (MST) is a surgical technique designed to treat ...rea that cannot be surgically resected without cau... technique, fine parallel cuts are made in the cor... seizure discharge without compromising the vertic...
...s were developed to reproducibly and accurately cr... double bundle PCL reconstruction. The guides simp...teromedial femoral tunnel sockets drilled endoscop...erolateral tunnel placement a guide can be used ei...
...t offers surgeons an alternative to traditional ar...hammertoe deformity. The prosthesis is constructed...ed for the proximal interphalangeal joints of digi...atomic hinge design similar to that used in digita...
The primary objective of the BioPro Toe implant is to provide a durable arthroplasty that will relieve pain and restore motion while leaving the biomechanical arrangement of the foot undisturbed. The
Medicine Products: